Amtagvi's 44% Melanoma Response Rate Unlocks $86.7M Revenue Surge, Fast Track Status for 7× Larger Lung Cancer Market
TL;DR
* Iovance Biotherapeutics reports $86.7M Q4 revenue, 50% gross margin on FDA-approved T-cell therapy Amtagvi
* Ascend Capital Partners raises $791M for second healthcare private equity fund targeting provider services and IT platforms
* Wayve secures £1.01 billion funding from Microsoft, NVIDIA, and Uber to deploy zero-shot autonomous driving